Potential Immunological Action of Purine Nucleoside Analogues

Overview

Journal Drugs

Specialty Pharmacology

Date 1994 Jan 1

PMID 7525190

Authors

G Dighiero

Affiliations

Soon will be listed here.

Abstract

Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported. However, the toxic effects on resting lymphocytes observed during treatment of lymphoid malignancies may potentially be of some benefit in patients with autoimmune diseases. To substantiate this possibility, a considerable amount of work needs to be carried out in order to better define the mechanism of action of these drugs, as well as their potential activity on different immunological effectors. Also, studies in animal models of autoimmune disease should be undertaken.

References

Carson D, Wasson D, Lakow E, Kamatani N . Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci U S A. 1982; 79(12):3848-52. PMC: 346525. DOI: 10.1073/pnas.79.12.3848. View

Carson D, Seegmiller J . Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J Clin Invest. 1976; 57(2):274-82. PMC: 436651. DOI: 10.1172/JCI108278. View

Schwartz L, Osborne B . Programmed cell death, apoptosis and killer genes. Immunol Today. 1993; 14(12):582-90. DOI: 10.1016/0167-5699(93)90197-S. View

Plunkett W, Gandhi V, Huang P, Robertson L, Yang L, Gregoire V . Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993; 20(5 Suppl 7):2-12. View

Carson D, Seto S, Wasson D, Carrera C . DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res. 1986; 164(2):273-81. DOI: 10.1016/0014-4827(86)90028-5. View

Carson D, Wasson D, Kaye J, Ullman B, Martin Jr D, ROBINS R . Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980; 77(11):6865-9. PMC: 350391. DOI: 10.1073/pnas.77.11.6865. View

Huang P, Plunkett W . Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol. 1991; 39(4):449-55. View

Piro L, Carrera C, Beutler E, Carson D . 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988; 72(3):1069-73. View

Huang A, Logue G, Engelbrecht G . Two biochemical markers in lymphocyte subpopulations. Br J Haematol. 1976; 34(4):631-8. DOI: 10.1111/j.1365-2141.1976.tb03610.x. View

10.

Martin Jr D, Gelfand E . Biochemistry of diseases of immunodevelopment. Annu Rev Biochem. 1981; 50:845-77. DOI: 10.1146/annurev.bi.50.070181.004213. View

11.

Hirschhorn R, Ratech H . Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase and their implications for therapy of leukemias. Curr Top Hematol. 1983; 4:1-35. View

12.

Boerrigter M . DNA strand break metabolism in human lymphocytes: a reevaluation. Exp Cell Res. 1991; 196(1):1-5. DOI: 10.1016/0014-4827(91)90448-4. View

13.

Carson D, Kaye J, Seegmiller J . Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977; 74(12):5677-81. PMC: 431856. DOI: 10.1073/pnas.74.12.5677. View

14.

Priebe T, Platsoucas C, Nelson J . Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res. 1990; 50(14):4328-31. View

15.

Wortmann R, Mitchell B, Edwards N, Fox I . Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A. 1979; 76(5):2434-7. PMC: 383616. DOI: 10.1073/pnas.76.5.2434. View

16.

DOnofrio J, Coleman M, HUTTON J, Daoud A, Lampkin B, Dyminski J . Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest. 1978; 62(4):884-7. PMC: 371841. DOI: 10.1172/JCI109201. View

17.

Priebe T, Kandil O, Nakic M, Pan B, Nelson J . Selective modulation of antibody response and natural killer cell activity by purine nucleoside analogues. Cancer Res. 1988; 48(17):4799-803. View

18.

Priebe T, Ruiz L, Nelson J . Role of natural killer cells in the modulation of primary antibody production by purine nucleosides and their analogs. Cell Immunol. 1990; 130(2):513-9. DOI: 10.1016/0008-8749(90)90291-x. View

19.

Carson D, Wasson D, Taetle R, Yu A . Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983; 62(4):737-43. View

20.

Robertson L, Chubb S, Meyn R, Story M, Ford R, Hittelman W . Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood. 1993; 81(1):143-50. View